Cancer Institute A national cancer institute
designated cancer center

Dean W. Felsher

Publication Details

  • Sustained loss of a neoplastic phenotype by brief inactivation of MYC SCIENCE Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., BISHOP, J. M., Felsher, D. W. 2002; 297 (5578): 102-104

    Abstract:

    Pharmacological inactivation of oncogenes is being investigated as a possible therapeutic strategy for cancer. One potential drawback is that cessation of such therapy may allow reactivation of the oncogene and tumor regrowth. We used a conditional transgenic mouse model for MYC-induced tumorigenesis to demonstrate that brief inactivation of MYC results in the sustained regression of tumors and the differentiation of osteogenic sarcoma cells into mature osteocytes. Subsequent reactivation of MYC did not restore the cells' malignant properties but instead induced apoptosis. Thus, brief MYC inactivation appears to cause epigenetic changes in tumor cells that render them insensitive to MYC-induced tumorigenesis. These results raise the possibility that transient inactivation of MYC may be an effective therapy for certain cancers.

    View details for Web of Science ID 000176711000043

    View details for PubMedID 12098700

Stanford Medicine Resources:

Footer Links: